MCS in the Treatment of Lower Urinary Tract Symptoms

NCT01002417 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

274

Enrollment

INDUSTRY

Sponsor class

Conditions

Lower Urinary Tract Symptoms
Benign Prostatic Hyperplasia

Interventions

DRUG: MCS-2 15 mg/day
DRUG: MCS-2 30 mg/day
DRUG: Placebo

Sponsor

Health Ever Bio-Tech Co., Ltd.